Table 1 SIFRA indicators
Rating 1 | |
|---|---|
Radiology and Laboratory Findings | Mean (Range) |
Presence of RF Ever | 2.7 (2–4) |
Presence of HLA Subtype | 3.0 (1–4) |
C1-2 Subluxation | 5.2 (5–6) |
Presence of CCP Ever | 3.0 (2–4) |
Clinical and Functional Status Measures | |
Number of Rheumatologist Visits | 3.2 (2–4) |
Extra-articular Manifestations | |
Pulmonary Nodules | 3.5 (3–5) |
Subcutaneous Nodules | 2.8 (2–4) |
Vasculitis Ever | 5.0 (4–6) |
Felty's Syndrome Ever | 5.0 (4–6) |
Surgical History | |
Cervical Spine Fusion | 5.5 (5–6) |
Foot Joint Replacement | 4.2 (2–6) |
Total Hip Replacement | 5.2 (4–6) |
Total Knee Replacement | 5.2 (4–6) |
Elbow Replacement | 5.3 (4–6) |
Shoulder Replacement | 5.5 (5–6) |
Medications | |
Any Oral Glucocorticoid Use | 2.8 (2–4) |
Intra-articular Glucocorticoids | 2.7 (2–4) |
Disease-modifying Anti-rheumatic Drugs | |
Azathioprine | 4.2 (3–5) |
Cyclosporin | 4.5 (4–5) |
Hydroxychloroquine | 2.0 (2) |
Leflunomide | 3.8 (3–4) |
Methotrexate | 3.8 (3–4) |
Sulfasalazine | 2.3 (2–3) |
Biologic Therapies | |
Adalimumab | 4.2 (4–5) |
Infliximab | 4.0 (3–5) |
Etanercept | 4.2 (4–5) |
TNF (ADA, ETN, IFX) | 4.1 |
Non-TNF (ABA, RTX) | 4.8 |